Hantz Financial Services, Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Hantz Financial Services, Inc.
- $6.19 Billion
- Q2 2025
A detailed history of Hantz Financial Services, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 375 shares of CPRX stock, worth $7,646. This represents 0.0% of its overall portfolio holdings.
Number of Shares
375
Previous 3
12400.0%
Holding current value
$7,646
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
388Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$381 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$179 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$112 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$66.3 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$64.9 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.1B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...